1057 HBM7008, a first-in-class bispecific antibody targeting both B7-H4 and 4–1BB, exhibits robust anti-tumor immunity and low toxicity through B7-H4-directed 4–1BB activation

Autor: Bing Huang, Fangfang Du, Xiaocheng Lv, Jianxun Zhao, Fei Chen, Zailian Lu, Yang Zhang, Victor Chen, Xin Gan, Jiuqiao Zhao, Yun He, Xiaodong Wu, Yiping Rong

Publikováno v: Regular and Young Investigator Award Abstracts.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ebd88dbadbea90ccee8c72ccfb5bb693
https://doi.org/10.1136/jitc-2022-sitc2022.1057

Development of BET inhibitors as potential treatments for cancer: A new carboline chemotype

Autor: Andrew P. Degnan, Haiquan Fang, Tatyana Zvyaga, Zuzana Haarhoff, Claude A. Quesnelle, Melissa Kramer, Frank Marsilio, Richard A. Westhouse, John S. Tokarski, Shilpa Madari, Jiuqiao Zhao, Amy Wiebesiek, Chunhong Yan, Francis Y. Lee, Michael Sinz, John Morrison, Jean Simmermacher-Mayer, Carolynn Fanslau, Steven Sheriff, Lisa Huang, Ashvinikumar V. Gavai, Chunshan Xie, Matthew D. Hill, Gerry Everlof

Publikováno v: Bioorganicmedicinal chemistry letters. 51

We describe our efforts to introduce structural diversity to a previously described triazole-containing N1-carboline series of bromodomain and extra-terminal (BET) inhibitors. N9 carbolines were designed to retain favorable binding interactions that

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ada735600c02c9c410a77e52ab96e515
https://pubmed.ncbi.nlm.nih.gov/34560263

Abstract 4098: A heavy chain only antibody against CTLA4 with outstanding preclinical efficacy and safety profile

Autor: Yiping Rong, Huayan Duan, Jiuqiao Zhao, Yun He, George Liu, Xin Gan

Publikováno v: Cancer Research. 79:4098-4098

Anti-CTLA-4 antibodies are one of the only three types of immune checkpoint inhibitors (together with anti-PD-1 and anti-PD-L1 antibodies) with proven monotherapy value in cancer therapy. Despite demonstrated efficacy, their broad application in mono

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9e46f2366d738cd305b5fefd0a2c6fd6
https://doi.org/10.1158/1538-7445.am2019-4098

Identification of a novel allosteric binding site in the CXCR2 chemokine receptor

Autor: Herman D. Lim, Douglas S. Auld, Maria L. Webb, Jac C. H. M. Wijkmans, Jiuqiao Zhao, Luc Roumen, Rob Leurs, Chris de Graaf, Petra de Kruijf, Martine J. Smit, Véronique A. Renjaän, G.J.R. Zaman

Publikováno v: Molecular Pharmacology, 80, 1108-1118. American Society for Pharmacology and Experimental Therapeutics
de Kruijf, P, Lim, H D, Roumen, L, Renjaan, V A, Zhao, J, Webb, M J, Auld, D A, Wijkmans, J C H M, Zaman, G J R, Smit, M J, de Graaf, C & Leurs, R 2011, ' Identification of a novel allosteric binding site in the CXCR2 chemokine receptor ', Molecular Pharmacology, vol. 80, pp. 1108-1118 . https://doi.org/10.1124/mol.111.073825

We have shown previously that different chemical classes of small-molecule antagonists of the human chemokine CXCR2 receptor interact with distinct binding sites of the receptor. Although an intracellular binding site for diarylurea CXCR2 antagonists

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::411a011ebb508fbe8e7aa0a7af6983a3
https://doi.org/10.1124/mol.111.073825

Conversion of C57Bl/6 mice from a tumor promotion-resistant to a -sensitive phenotype by enhanced ornithine decarboxylase expression

Autor: Janet A. Sawicki, Yongjun Guo, Alejandro Peralta Soler, Jiuqiao Zhao, Thomas G. O'Brien

Publikováno v: Molecular Carcinogenesis. 26:32-36

A transgenic mouse model was developed in which ornithine decarboxylase (ODC) can be overexpressed in a tissue-specific and regulated manner. Hair follicle keratinocytes were targeted by use of a bovine keratin 6 (K6) promoter/regulatory region, and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf3fd98797b08eb37db3b5c0ce632f67
https://doi.org/10.1002/(sici)1098-2744(199909)26:1<32::aid-mc4>3.0.co